MONTI, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.046
EU - Europa 5.979
AS - Asia 4.441
SA - Sud America 463
AF - Africa 130
OC - Oceania 93
Continente sconosciuto - Info sul continente non disponibili 3
Totale 22.155
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.948
RU - Federazione Russa 2.464
SG - Singapore 1.271
CN - Cina 1.027
HK - Hong Kong 746
PL - Polonia 701
IE - Irlanda 610
SE - Svezia 541
VN - Vietnam 479
IT - Italia 418
BR - Brasile 372
KR - Corea 365
DE - Germania 259
FI - Finlandia 254
UA - Ucraina 226
FR - Francia 201
GB - Regno Unito 148
IN - India 129
TR - Turchia 105
JP - Giappone 100
AU - Australia 91
CA - Canada 54
CI - Costa d'Avorio 50
AR - Argentina 40
ID - Indonesia 35
JO - Giordania 33
BE - Belgio 31
BD - Bangladesh 30
NL - Olanda 29
IQ - Iraq 28
MX - Messico 23
CH - Svizzera 20
ZA - Sudafrica 17
EC - Ecuador 15
ES - Italia 14
NG - Nigeria 14
CO - Colombia 13
KE - Kenya 11
PH - Filippine 11
AE - Emirati Arabi Uniti 10
CZ - Repubblica Ceca 10
LT - Lituania 10
UZ - Uzbekistan 10
MA - Marocco 9
SA - Arabia Saudita 9
EG - Egitto 8
PK - Pakistan 8
RO - Romania 8
AZ - Azerbaigian 7
VE - Venezuela 7
PE - Perù 6
SC - Seychelles 6
TW - Taiwan 6
DO - Repubblica Dominicana 5
AM - Armenia 4
DK - Danimarca 4
JM - Giamaica 4
KG - Kirghizistan 4
PY - Paraguay 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BO - Bolivia 3
CR - Costa Rica 3
ET - Etiopia 3
EU - Europa 3
GR - Grecia 3
HN - Honduras 3
KZ - Kazakistan 3
OM - Oman 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AT - Austria 2
BG - Bulgaria 2
BY - Bielorussia 2
CL - Cile 2
DZ - Algeria 2
GD - Grenada 2
HU - Ungheria 2
IL - Israele 2
LK - Sri Lanka 2
MD - Moldavia 2
MT - Malta 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
AL - Albania 1
BF - Burkina Faso 1
BH - Bahrain 1
BJ - Benin 1
CY - Cipro 1
GE - Georgia 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
Totale 22.151
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.621
Ashburn 972
Fairfield 870
Singapore 850
Warsaw 695
Dublin 609
Hong Kong 607
Chandler 588
San Jose 584
Woodbridge 404
Seoul 362
Seattle 353
Cambridge 345
Wilmington 336
Beijing 306
Jacksonville 296
Houston 290
The Dalles 228
Ann Arbor 207
Buffalo 199
Princeton 157
Ho Chi Minh City 154
Hefei 149
Los Angeles 140
Altamura 136
Lauterbourg 136
Lawrence 131
Boston 102
Hanoi 101
Tokyo 99
Boardman 97
Helsinki 90
Melbourne 87
Mumbai 87
Medford 84
Izmir 76
Dallas 73
Florence 67
Munich 64
Abidjan 50
New York 50
Bremen 48
Shanghai 46
Moscow 45
Norwalk 41
San Diego 40
Council Bluffs 37
Falls Church 33
Brussels 31
Paris 31
São Paulo 30
Redondo Beach 28
Turku 23
Da Nang 21
Frankfurt am Main 21
Jakarta 21
London 21
Milan 20
Dearborn 19
Bern 18
Dong Ket 18
Orem 18
Toronto 17
Kent 16
Andover 15
Atlanta 15
Guangzhou 15
Washington 15
Clifton 14
Haiphong 14
Hillsboro 14
Montreal 14
Abuja 13
Chicago 13
Stockholm 13
Baghdad 12
Brooklyn 12
West Jordan 12
Phoenix 11
Brasília 10
Can Tho 10
Tashkent 10
Denver 9
Hải Dương 9
Manchester 9
Padova 9
Rio de Janeiro 9
Belo Horizonte 8
Dhaka 8
Nairobi 8
Redmond 8
Rome 8
Salerno 8
Verona 8
Auburn Hills 7
Brno 7
Curitiba 7
Frankfurt Am Main 7
Guayaquil 7
Johannesburg 7
Totale 14.870
Salva come PNG Salva come JPEG
Nome #
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 316
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 313
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 292
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 260
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 256
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 253
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 253
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 242
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 229
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 223
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 222
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 220
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 220
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 220
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 219
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 217
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 213
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 207
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 203
Host genetic determinants in HCV-related mixed cryoglobulinemia 198
Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma 197
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 197
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 196
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 192
Host genetic determinants in HCV-related mixed cryoglobulinemia 190
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 185
Analysis of HCV persistence in patients with sustained virological response 184
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 181
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 180
Infection of peripheral mononuclear blood cells by hepatitis C virus 179
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 177
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 177
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 174
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 174
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients 171
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 171
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 170
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 170
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 168
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 167
Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients 167
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 167
Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia 166
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 165
Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications 164
Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool? 164
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection 164
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis 163
T(14;18) translocation in chronic hepatitis C virus infection 162
A PROSPECTIVE-STUDY ON THE PREVALENCE OF ANTI HCV ANTIBODIES AND HCV-RNA IN SERA OF HEMODIALYSIS-PATIENTS 161
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 161
Host genetic determinants in HCV-related mixed cryoglobulinemia 161
Can type C hepatitis infection be complicated by malignant lymphoma? 160
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 160
HCV INFECTION OF PERIPHERAL AND LIVER MONONUCLEAR-CELLS - PATHOGENIC IMPLICATIONS 156
Vertical transmission of HCV. 156
Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin's lymphoma 155
Applicazione della metodica PCR (polymerase chain reaction) ed altre tecniche di biologia molecolare allo studio dell'infezione da virus C dell'epatite. 155
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 155
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 153
Tryptophan/kynurenine pathway changes in HCV-infected patients: possible involvement in associated neuropsychiatry pathology 152
HCV infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. 150
Hepatitis C virus (HCV) in cryoglobulinaemic leukocytoclastic vasculitis (LCV): could the presence of HCV in skin lesions be related to T CD8+ lymphocytes, HLA-DR and ICAM-1 expression? 150
Hepatitis C virus infection and B-cell lymphomas 149
Hepatitis C virus infection in patients with non-Hodgkin's lymphoma 149
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 148
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 146
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 146
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 144
Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia 143
ANALYSIS OF HCV INFECTION IN PATIENTS WITH B-CELL NON-HODGKINS-LYMPHOMA 142
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 142
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 141
Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease 140
Efficacia del trattamento antivirale nell’indurre la regressione di cloni B cellulari alberganti la traslocazione t(14;18) nell’infezione cronica da virus C dell’epatite (HCV). 139
Tryptophan/Kynurenine pathway changes in HCV infected patients: possible involvment in associated neuropsychiathy pathology. 139
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 138
Safety and effectiveness of boceprevir triple therapy in patients with mixed cryoglobulinemia 138
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 138
Behaviour of sustained responders to anti-HCV treatment: may HCV infection be eradicated? 138
Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia 135
Analysis of HBV/HDV infection in the liver transplant model. 134
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 133
Hepatitis C virus lymphotropism and possible pathogenetic implications 133
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 133
Interferon-alpha in mixed cryoglobulinemia patients: a randomized crossover controlled trial 132
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 132
Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection 131
Type C hepatitis and chronic lymphocytic leukaemia 130
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 130
Comportamento dell'infezione da HCV in pazienti trapiantati per HCC complicante una cirrosi HCV-correlata 130
Epatite da virus C e terapia interferonica 130
Mixed cryoglobulinemia as a possible preneoplastic disorder 129
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 127
Tryptophan/kynurenine Patway Changes in HCV-infected Patients: Possible Involvement In Associated Neuropsychiatry Pathology 126
L'Impiego dell'INterferone Alfa Ricombinante nel Trattamento della Cirrosi Attiva anti-HCV positiva. 126
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 125
Interstitial lung fibrosis in patients with hepatitis C virus infection 124
Hepatitis C virus (HCV) infection of fresh and cultured peripheral blood mononuclear cells (PBMNC). 124
Hepatitis C virus as a lymphotropic agent: Evidence and pathogenetic implications 124
Totale 17.051
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.419
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.419
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021180 0 0 0 0 0 0 0 0 0 0 95 85
2021/20221.052 13 109 44 58 46 38 32 70 47 25 204 366
2022/20232.576 247 345 134 187 246 531 356 132 268 16 74 40
2023/2024756 39 118 163 31 46 116 11 150 11 22 24 25
2024/20256.898 223 696 457 1.027 2.342 823 82 376 336 124 225 187
2025/20266.033 817 929 478 439 697 258 848 317 681 441 128 0
Totale 22.215